Search Results - "Cejalvo, J. M."

Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A by Mouron, S., Bueno, M. J., Lluch, A., Manso, L., Calvo, I., Cortes, J., Garcia-Saenz, J. A., Gil-Gil, M., Martinez-Janez, N., Apala, J. V., Caleiras, E., Ximénez-Embún, Pilar, Muñoz, J., Gonzalez-Cortijo, L., Murillo, R., Sánchez-Bayona, R., Cejalvo, J. M., Gómez-López, G., Fustero-Torre, C., Sabroso-Lasa, S., Malats, N., Martinez, M., Moreno, A., Megias, D., Malumbres, M., Colomer, R., Quintela-Fandino, M.

“…Precision oncology research is challenging outside the contexts of oncogenic addiction and/or targeted therapies. We previously showed that phosphoproteomics…”
Get full text

In the literature: November 2022 by Gambardella, V., Cejalvo, J.-M., Cervantes, A.

Get full text

In the literature: May 2023 by Gambardella, V., Cejalvo, J.-M., Cervantes, A.

Get full text

In the Literature: January 2023 by Martín-Arana, J., Gambardella, V., Tarazona, N., Cejalvo, J.-M., Cervantes, A.

Get full text

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study by Oliveira, M., Falato, C., Cejalvo, J.M., Vila, M. Margelí, Tolosa, P., Salvador-Bofill, F.J., Cruz, J., Arumi, M., Luna, A.M., Guerra, J.A., Vidal, M., Martínez-Sáez, O., Paré, L., González-Farré, B., Sanfeliu, E., Ciruelos, E., Espinosa-Bravo, M., Pernas, S., Izarzugaza, Y., Esker, S., Fan, P.-D., Parul, P., Santhanagopal, A., Sellami, D., Villacampa, G., Ferrero-Cafiero, J.M., Pascual, T., Prat, A.

“…Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody–drug conjugate composed of a fully human anti-HER3…”
Get full text

Pharmacology of Ischemia-Reperfusion. Translational Research Considerations by Prieto-Moure, Beatriz, Lloris-Carsí, José M., Barrios-Pitarque, Carlos, Toledo-Pereyra, Luis-H., Lajara-Romance, José María, Berda-Antolí, M., Lloris-Cejalvo, J. M., Cejalvo-Lapeña, Dolores

“…Ischemia-reperfusion (IRI) is a complex physiopathological mechanism involving a large number of metabolic processes that can eventually lead to cell apoptosis…”
Get full text

Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma by Gambardella, V., Fleitas, T., Tarazona, N., Cejalvo, J.M., Gimeno-Valiente, F., Martinez-Ciarpaglini, C., Huerta, M., Roselló, S., Castillo, J., Roda, D., Cervantes, A.

“…Gastroesophageal adenocarcinoma (GEA) represents a very heterogeneous disease and patients in advanced stages have a very poor prognosis. Although several…”
Get full text

Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma by Blanes, M., Lorenzo, J. I., Ribas, P., Jiménez, A., González, J. D., Cejalvo, M. J., Solano, C., Alegre, A., de la Rubia, Javier

Get full text

In the literature: February 2021 by Cejalvo, J.M., Gambardella, V., Fleitas, T., Cervantes, A.

Get full text

In the literature: February 2022 by Gambardella, V., Cejalvo, J.M., González-Barrallo, I., Gimeno-Valiente, F., Cervantes, A.

Get full text

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer by Adam-Artigues, A., Garrido-Cano, I., Simón, S., Ortega, B., Moragón, S., Lameirinhas, A., Constâncio, V., Salta, S., Burgués, O., Bermejo, B., Henrique, R., Lluch, A., Jerónimo, C., Eroles, P., Cejalvo, J.M.

“…Recently, microRNAs have been demonstrated to be potential non-invasive biomarkers for diagnosis, prognosis assessment or prediction of response to treatment…”
Get full text

In the literature: August 2021 by Gambardella, V., Alfaro-Cervelló, C., Cejalvo, J.M., Tapia, M., Cervantes, A.

Get full text

In the literature: April 2021 by Martín-Martorell, P., Gonzalez-Barrallo, I., Gambardella, V., Cejalvo, J.M., Cervantes, A.

Get full text

In the literature: June 2021 by Gambardella, V., Candia, L., Tapia, M., Cejalvo, J.M., Cervantes, A.

Get full text

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer by Pérez-Fidalgo, J. A., Bermejo, B., Chirivella, I., Martínez, M. T., González, I., Cejalvo, J. M., Catoira, I., Martínez, P., Contel, E., Lluch, A.

“…Purpose To evaluate the impact on survival of the relative dose intensity (RDI) achieved in patients with early breast cancer receiving anthracycline plus…”
Get full text

P859: ANTI‐CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS by Meseguer Martinez, E., Marco Buades, J., García Feria, A., Ribas García, P., Fernandez Llavador, M. J., López Gabaldon, A., Broseta Tormos, S., Francés Aracil, E., Cortés Ortega, O., Donato Martínez, E., Fernandez Zarzoso, M., Panero Ruiz, M., Cejalvo Andújar, M. J., Tolosa Muñoz, A., Juan Marco, M. L., Ivars Santacreu, D., Gómez Beltrán, E., Sayas Lloris, M. J.

Get full text

P1527: NEXT GENERATION SEQUENCING IN HEREDITARY SPHEROCYTOSIS DIAGNOSIS by García Feria, A., Marco Buades, J., Zuñiga Cabrera, A., López Gabaldon, A., Broseta Tormos, S., Villa Velazquez, M. I., Fernandez Gayete, I., Gasco Clar, S., Rivera Garcia, P., Frances Aracil, E., Meseguer Martinez, E., Cortes Ortega, O., Donato Martinez, E., Fernandez Zarzoso, M., Juan Marco, M. L., Tolosa Muñoz, A., Gomez Beltran, E., Cejalvo Andujar, M. J., Panero Ruiz, M., Ribas Garcia, P., Fernandez Llavador, M. J., Sayas Lloris, M. J.

Get full text

321PClinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine by Cejalvo, J M, Moragon, S, Ortega, B, Hernando, C, Martínez, M, Gambardella, V, Tarazona Llavero, N, Roda, D, Burgues, O, Alonso, E, Simón, S, Poveda, J, Rentero, P, Zuñiga, S, Bermejo, B, Lluch, A, Cervantes, A

“…Abstract Background The identification of biomarkers to drive treatment is one of the most important objectives of precision medicine. During last years, the…”
Get full text

319PThe role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach by Adam-Artigues, A, Tormo, E, Rojo, F, Perez-Fidalgo, J A, Zazo, S, Gonzalez-Alonso, P, Hernando, C, Martínez, M T, Gambardella, V, Poveda, J, Simón, S, Moragon, S, Alonso, E, Rovira, A, Albanell, J, Burgues, O, Bermejo, B, Eroles, P, Lluch, A, Cejalvo, J M

“…Abstract Background Breast cancer (BC) is a heterogeneous disease. HER2+ BC represents between 15-30% of cases. Trastuzumab (T), a monoclonal antibody, has…”
Get full text

A phase Ib study of lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with carboplatin and paclitaxel as 1st-line treatment in patients with squamous non-small cell lung cancer by Cejalvo, J.M., Fleitas, T., Felip, E., Mendivil, A. Navarro, Martinez-Garcia, M., Taus, A., Leighl, N., Lassen, U., Soerensen, M. Mau, Adessi, C., Michielin, F., Jacob, W., James, I., Ceppi, M., Weisser, M., Cervantes, A.

Get full text